{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T14:54:37Z","timestamp":1758120877988},"publisher-location":"Chichester, UK","reference-count":35,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd006300.pub2","type":"reference-entry","created":{"date-parts":[[2010,2,17]],"date-time":"2010-02-17T14:30:39Z","timestamp":1266417039000},"source":"Crossref","is-referenced-by-count":5,"title":["Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients"],"prefix":"10.1002","author":[{"given":"Ren\u00e9e L","family":"Mulder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios","family":"Paulides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leontien CM","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira C","family":"van Dalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,2,17]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD006300.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.2000.18.12.2427","article-title":"Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV","volume":"18","author":"Baker","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006300.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/BF00647440","article-title":"Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas","volume":"18","author":"Bramwell","year":"1986","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006300.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0277-5379(87)90075-7","article-title":"Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas","volume":"23","author":"Bramwell","year":"1987","journal-title":"European Journal of Cancer & Clinical Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006300.pub2-BIB4|cit4","first-page":"S180","article-title":"Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer (EORTC), Soft Tissue and Bone Sarcoma Group","volume":"31","author":"Bramwell","year":"1993","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1002\/14651858.CD006300.pub2-BIB5|cit5","series-title":"ASCO Annual Meeting","first-page":"Abstract no 214","article-title":"Preliminary results for patients with local\/regional tumors treated on the intergroup rhabdomyosarcoma study-IV (1991-97)","author":"Crist","year":"1999"},{"issue":"12","key":"10.1002\/14651858.CD006300.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2001.19.12.3091","article-title":"Intergroup rhabdomyosarcoma study - IV: results for patients with nonmetastatic disease","volume":"19","author":"Crist","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD006300.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0360-3016(98)00228-4","article-title":"Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies","volume":"42","author":"Dunst","year":"1998","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD006300.pub2-BIB8|cit8","series-title":"ASCO Annual Meeting","first-page":"Abstract no 228","article-title":"European Intergroup Cooperative Ewing's Sarcoma Study (EICESS92): first results","author":"Jurgens","year":"2000"},{"issue":"4","key":"10.1002\/14651858.CD006300.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1055\/s-2008-1043800","article-title":"EICESS 92 (European Intergroup Cooperative Ewing's Sarcoma Study) - preliminary results","volume":"211","author":"Paulussen","year":"1999","journal-title":"Klinische Padiatrie"},{"issue":"11","key":"10.1002\/14651858.CD006300.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1023\/A:1013148730966","article-title":"Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German\/Austrian\/Dutch study","volume":"12","author":"Paulussen","year":"2001","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006300.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ejca.2009.01.002","article-title":"Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens","volume":"45","author":"Ridola","year":"2009","journal-title":"European Journal of Cancer"},{"issue":"12","key":"10.1002\/14651858.CD006300.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1200\/JCO.2005.08.130","article-title":"Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology - SIOP Malignant Mesenchymal Tumor 89","volume":"23","author":"Stevens","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD006300.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.1988.6.2.329","article-title":"Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response","volume":"6","author":"Winkler","year":"1988","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006300.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/ctrv.1998.0098","article-title":"The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer","volume":"25","author":"Burke","year":"1999","journal-title":"Cancer Treatment Reviews"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006300.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000073369","article-title":"Ifosfamide in pediatric solid tumors","volume":"65","author":"Carli","year":"2003","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD006300.pub2-BIB16|cit16","first-page":"61","article-title":"Ifosfamide vs. cyclophosphamide: long term gonadal effects in male survivors of childhood cancer","volume":"9","author":"Fawaz","year":"2005","journal-title":"Sarcoma"},{"key":"10.1002\/14651858.CD006300.pub2-BIB17|cit17","doi-asserted-by":"crossref","unstructured":"German Childhood Cancer Registry: Annual Report 2004 http:\/\/www.kinderkrebsregister.de\/texte04pdf\/6_22.pdf (accessed 15 December 2005)","DOI":"10.1016\/S1526-8209(11)70697-8"},{"key":"10.1002\/14651858.CD006300.pub2-BIB18|cit18","unstructured":"German Childhood Cancer Registry: Annual Report 2004 Appendix http:\/\/www.kinderkrebsregister.de\/texte04pdf\/taba1te2.pdf (accessed 15 December 2005)"},{"key":"10.1002\/14651858.CD006300.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.critrevonc.2004.08.007","article-title":"Pharmacokinetic studies in children with cancer","volume":"52","author":"Groninger","year":"2004","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1002\/14651858.CD006300.pub2-BIB20|cit20","unstructured":"Higgins J Green S (eds.) Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Collaboration 2005 http:\/\/www.cochrane.org\/resources\/handbook\/hbook.htm"},{"key":"10.1002\/14651858.CD006300.pub2-BIB21|cit21","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD006300.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/humupd\/7.4.363","article-title":"Testicular function following chemotherapy","volume":"7","author":"Howell","year":"2001","journal-title":"Human Reproduction Update"},{"key":"10.1002\/14651858.CD006300.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000085704","article-title":"Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?","volume":"68","author":"Kasper","year":"2005","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD006300.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1440-1797.2005.00372.x","article-title":"Treatment for lupus nephritis: a revisit","volume":"10","author":"Lai","year":"2005","journal-title":"Nephrology (Carlton)"},{"key":"10.1002\/14651858.CD006300.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1200\/JCO.2001.19.6.1818","article-title":"Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86","volume":"19","author":"Paulussen","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006300.pub2-BIB26|cit26","first-page":"286","article-title":"Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor","volume":"16","author":"Raney","year":"1994","journal-title":"American Journal of Pediatric Hematology\/Oncology"},{"key":"10.1002\/14651858.CD006300.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s004670050585","article-title":"Renal involvement in children with malignancies","volume":"13","author":"Rossi","year":"1999","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD006300.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/0140-6736(90)91076-M","article-title":"Ifosfamide in paediatric oncology: tried but not tested?","volume":"335","author":"Shaw","year":"1990","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006300.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00148581-200507030-00005","article-title":"Cardiotoxicity of cancer chemotherapy: implications for children","volume":"7","author":"Simbre","year":"2005","journal-title":"Paediatric Drugs"},{"key":"10.1002\/14651858.CD006300.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mpo.10336","article-title":"Chronic ifosfamide nephrotoxicity in children","volume":"41","author":"Skinner","year":"2003","journal-title":"Medical and Pediatric Oncology"},{"key":"10.1002\/14651858.CD006300.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1158\/1078-0432.CCR-04-0654","article-title":"Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group","volume":"10","author":"Spunt","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD006300.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/pbc.20920","article-title":"Growth impairment after ifosfamide-induced nephrotoxicity in children","volume":"48","author":"St\u00f6hr","year":"2007","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD006300.pub2-BIB33|cit33","first-page":"605","article-title":"Biology and therapy of malignant solid tumors in childhood","volume":"20","author":"Berg","year":"2002","journal-title":"Cancer Chemotherapy and Biological Response Modifiers"},{"key":"10.1002\/14651858.CD006300.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s00393-005-0750-4","article-title":"The treatment of juvenile rheumatism: pharmacotherapy","volume":"64","author":"Weller","year":"2005","journal-title":"Zeitschrift fur Rheumatologie"},{"key":"10.1002\/14651858.CD006300.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.drup.2005.08.003","article-title":"Insights into oxazaphosphorine resistance and possible approaches to its circumvention","volume":"8","author":"Zhang","year":"2005","journal-title":"Drug Resistance Updates"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006300.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:32:41Z","timestamp":1685435561000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006300.pub2"}},"subtitle":[],"editor":[{"given":"Ren\u00e9e L","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2010,2,17]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006300.pub2","relation":{},"subject":[],"published":{"date-parts":[[2010,2,17]]}}}